Myocardial infarction following COVID-19 vaccine administration; a systematic review
| Autor: | Dana H. Baqi, Fahmi H. Kakamad, Zana H. Mahmood, Fattah H. Fattah, Shaho F. Ahmed, Marwan N. Hassan, Bnar J. Hama Amin, Shvan H. Mohammed, Tomas M. Mikael, Hunar A. Hassan, Abdulwahid M. Salh |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Heliyon, Vol 8, Iss 11, Pp e11385- (2022) |
| Druh dokumentu: | article |
| ISSN: | 2405-8440 32677545 |
| DOI: | 10.1016/j.heliyon.2022.e11385 |
| Popis: | Introduction: Covid-19 vaccines have been assessed in randomized trials, which are designed to establish efficacy and safety, but are insufficient in power to detect rare adverse outcomes. Among the adverse cardiac events associated with mRNA COVID-19 vaccines are inflammations (e.g., pericarditis or myocarditis), thrombosis, and ischemia. Objective: This systematic review aims to evaluate the reported cases of myocardial infarction (MI) after COVID-19 vaccinations. Method: Web of Science, MEDLINE on OVID, PubMed, and Google Scholar were searched for English-language papers published until March 25, 2022. Results: This study included 15 papers (10 case reports and 5 case series). In total, 20 individuals were included who had received COVID-19 vaccines and experienced MI. Males (55%) reported more adverse occurrences than females (45%) across the majority of event categories. The mean time from the administration of the vaccine to the onset of symptoms was 2 days (0–10 days). The AstraZeneca vaccine was responsible for more than half of the reported events. In the majority of cases, the event developed after receiving the first dose of vaccination. Conclusion: MI related to COVID19 vaccination is a rare, but serious and life-threatening condition. Chest discomfort should be regarded as a warning sign, particularly in people who have been administered a dose of the vaccine within the previous two days. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|